This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sica, D. A Articles by Gehr, T. W. Search for Related Content PubMed PubMed Citation Articles by Sica, D. A Articles by Gehr, T. W. Social Bookmarking                         What's this?

Review: The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease

Section of Clinical Pharmacology and Hypertension, dsica@ hsc.vcu.edu

Todd WB Gehr

Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia, USA

Angiotensin-converting enzyme (ACE) inhibitors and more recently angiotensin-receptor blockers (ARBs) have become popular therapies in the end-stage renal disease (ESRD) patient. The ability of either of these drug classes to reduce blood pressure in the ESRD patient is well accepted; however, there is considerably less information available to guide the clinician in the safe and effective use of these drugs in the ESRD patient with congestive heart failure and/or coronary artery disease. Head-to-head studies in the ESRD patient are lacking for both drug classes. Several pharmacokinetic factors can influence the selection of these drugs, including dialysability and the propensity for systemic accumulation. ACE inhibitors (ACE-Is) and ARBs are recognised as having a range of nonpressor effects that are pertinent to patients with ESRD. Such effects include their ability to decrease both thirst drive and erythropoiesis. These drug classes, though, are distinguishable by the unique adverse effect profile for ACE-Is. As is the case in patients without renal failure, ESRD patients can experience cough and, less frequently, angioneurotic oedema with ACE-Is. In the ESRD population, so-called anaphylactoid dialyser reactions can occur in conjunction with ACE-I use. The use of a drug from within the ARB class carries both less risk and permits a compound with a preferred pharmacokinetic profile — limited dialysability and minimal systemic accumulation — to be administered. These attributes would favour the increased use of ARBs in this population.

Key Words: ACE inhibitors • angiotensin-receptor blockers • anaemia • thirst • congestive heart failure • hypertension • haemodialysis • pharmacokinetics

Journal of Renin-Angiotensin-Aldosterone System, Vol. 3, No. 4, 247-254 (2002)
DOI: 10.3317/jraas.2002.046


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?